Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, on Aug. 9 announced an exclusive, binding letter of intent with GEDi Cube. Today Renovaro BioSciences congratulated GEDi Cube on its appointment of Dr. Lester Russell as its chief medical officer. “We are excited about the appointment of Dr. Russell,” said Dr. Mark Dybul, CEO of Renovaro BioSciences. “As a seasoned expert in clinical medicine and digital health, he could enhance the capabilities of GEDi Cube to make a difference in the lives of people at risk of or suffering from serious illnesses.”
To view the full press release, visit https://ibn.fm/9CMOu
About Renovaro BioSciences Inc.
Renovaro BioSciences, formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as human immunodeficiency virus (“HIV”) and hepatitis B virus (“HBV”) infection. For more information, visit the company’s website at https://enochianbio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
